Background: Antifungal agents incorporated into temporary denture resilient liners as drug
carriers and delivery have been suggested as an alternative treatment for denture stomatitis. However,
to test the in vivo biocompatibility of this protocol, standardization of an intraoral device for optimal
drug delivery is required.
Objective: Standardized criteria were produced to adjust an acrylic intraoral device (IOD) for rats feasible
for denture stomatitis treatment by sustained drug-delivery based on minimal inhibitory drug
concentrations (MICs) of antifungals for Candida albicans biofilm.
Method: Adjustments methodological involved diet, impression technique, type of retention device to
the palate and histopathological analysis. 115 Wistar rats were tested without IOD, with devices without
relining or relined with temporary resilient material (Trusoft) modified or not by drugs at MICs
(nystatin-0.032g/mL; chlorhexidine diacetate-0.064g/mL; ketoconazole-0.128g/mL). The animals were
sacrificed after 7 or 14 days from the IOD installation.
Results: Paste diet enabled the best animal survival conditions. The IODs that most satisfactorily
remained in position were those designed only to the posterior palatal mucosa and cement-retained in
molars, being all obtained from impressions highly detained and individual. In both periods, Trusoft
without/with drugs showed good performance. Only histological samples from hard/soft tissues were
considered appropriate for region of interest-RI determination (n=12), which corresponded to the area
restricted to the first molars between the palatal neurovascular bundles. Final samples of all groups allowed
a standardized descriptive histopathological analysis in both periods.
Conclusion: The methodological standardization of this rat model resulted in IODs for optimal antifungal
delivery for denture stomatitis treatment.